Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 6
2008 16
2009 29
2010 45
2011 69
2012 164
2013 257
2014 277
2015 285
2016 313
2017 361
2018 369
2019 390
2020 432
2021 420
2022 351
2023 271
2024 87

Text availability

Article attribute

Article type

Publication date

Search Results

3,547 results

Results by year

Filters applied: . Clear all
Page 1
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review.
Byon W, Garonzik S, Boyd RA, Frost CE. Byon W, et al. Clin Pharmacokinet. 2019 Oct;58(10):1265-1279. doi: 10.1007/s40262-019-00775-z. Clin Pharmacokinet. 2019. PMID: 31089975 Free PMC article. Review.
Apixaban exposure increases dose proportionally for oral doses up to 10 mg. ...The pharmacodynamic effect of apixaban is closely correlated with apixaban plasma concentration. ...
Apixaban exposure increases dose proportionally for oral doses up to 10 mg. ...The pharmacodynamic effect of apixaban is close …
Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial.
Pokorney SD, Chertow GM, Al-Khalidi HR, Gallup D, Dignacco P, Mussina K, Bansal N, Gadegbeku CA, Garcia DA, Garonzik S, Lopes RD, Mahaffey KW, Matsuda K, Middleton JP, Rymer JA, Sands GH, Thadhani R, Thomas KL, Washam JB, Winkelmayer WC, Granger CB; RENAL-AF Investigators. Pokorney SD, et al. Circulation. 2022 Dec 6;146(23):1735-1745. doi: 10.1161/CIRCULATIONAHA.121.054990. Epub 2022 Nov 6. Circulation. 2022. PMID: 36335914 Clinical Trial.
Median steady-state 12-hour area under the curve was 2475 ng/mLh (10th to 90th percentiles, 1342-3285) for 5 mg of apixaban twice daily and 1269 ng/mLh (10th to 90th percentiles, 615-1946) for 2.5 mg of apixaban twice daily. There was substantial overlap between min …
Median steady-state 12-hour area under the curve was 2475 ng/mLh (10th to 90th percentiles, 1342-3285) for 5 mg of apixaban twice dai …
Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study.
Lau WCY, Torre CO, Man KKC, Stewart HM, Seager S, Van Zandt M, Reich C, Li J, Brewster J, Lip GYH, Hingorani AD, Wei L, Wong ICK. Lau WCY, et al. Ann Intern Med. 2022 Nov;175(11):1515-1524. doi: 10.7326/M22-0511. Epub 2022 Nov 1. Ann Intern Med. 2022. PMID: 36315950
OBJECTIVE: To do a large-scale comparison between all DOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) in routine clinical practice. ...RESULTS: A total of 527 226 new DOAC users met the inclusion criteria (apixaban, n = 281 320; dabigatran, n = 61 008; edoxa …
OBJECTIVE: To do a large-scale comparison between all DOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) in routine clinical pra …
Apixaban vs. warfarin in patients with left ventricular thrombus: a prospective multicentre randomized clinical trial.
Alcalai R, Butnaru A, Moravsky G, Yagel O, Rashad R, Ibrahimli M, Planer D, Amir O, Elbaz-Greener G, Leibowitz D. Alcalai R, et al. Eur Heart J Cardiovasc Pharmacother. 2022 Sep 29;8(7):660-667. doi: 10.1093/ehjcvp/pvab057. Eur Heart J Cardiovasc Pharmacother. 2022. PMID: 34279598 Clinical Trial.
In the warfarin group, two patients withdrew, and in the apixaban group one patient died. Thrombus completely resolved in 14 of 15 patients in the warfarin group and in 16 of 17 patients in the apixaban group (P = NS and P = 0.026 for non-inferiority). Two patients …
In the warfarin group, two patients withdrew, and in the apixaban group one patient died. Thrombus completely resolved in 14 of 15 pa …
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, Perepu U, Anderson D, Gundabolu K, Kuzma C, Perez Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Houghton DE, Vishnu P, Loprinzi CL. McBane RD 2nd, et al. J Thromb Haemost. 2020 Feb;18(2):411-421. doi: 10.1111/jth.14662. Epub 2019 Nov 28. J Thromb Haemost. 2020. PMID: 31630479 Free article. Clinical Trial.
Metastatic disease was present in 66% of subjects; 74% were receiving concurrent chemotherapy. Major bleeding occurred in 0% of 145 patients receiving apixaban, compared with 1.4% of 142 patients receiving dalteparin [P = .138; hazard ratio (HR) not estimable because of 0 …
Metastatic disease was present in 66% of subjects; 74% were receiving concurrent chemotherapy. Major bleeding occurred in 0% of 145 patients …
Apixaban Versus Rivaroxaban in Patients With Atrial Fibrillation and Valvular Heart Disease : A Population-Based Study.
Dawwas GK, Cuker A, Barnes GD, Lewis JD, Hennessy S. Dawwas GK, et al. Ann Intern Med. 2022 Nov;175(11):1506-1514. doi: 10.7326/M22-0318. Epub 2022 Oct 18. Ann Intern Med. 2022. PMID: 36252244 Free PMC article. Clinical Trial.
OBJECTIVE: To emulate a target trial of effectiveness and safety of apixaban and rivaroxaban in patients with AF and VHD. DESIGN: New-user, active comparator, cohort study design. ...The absolute reduction in the probability of bleeding events with apixaban compared …
OBJECTIVE: To emulate a target trial of effectiveness and safety of apixaban and rivaroxaban in patients with AF and VHD. DESIGN: New …
Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients.
Mavrakanas TA, Samer CF, Nessim SJ, Frisch G, Lipman ML. Mavrakanas TA, et al. J Am Soc Nephrol. 2017 Jul;28(7):2241-2248. doi: 10.1681/ASN.2016090980. Epub 2017 Mar 16. J Am Soc Nephrol. 2017. PMID: 28302754 Free PMC article.
Seven patients received apixaban 2.5 mg twice daily for 8 days. Blood samples were collected before and after apixaban administration on days 1 and 8 (nondialysis days). ...Apixaban 5 mg twice daily led to supratherapeutic levels in patients on hemodialysis a …
Seven patients received apixaban 2.5 mg twice daily for 8 days. Blood samples were collected before and after apixaban adminis …
Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data.
Jamieson MJ, Byon W, Dettloff RW, Crawford M, Gargalovic PS, Merali SJ, Onorato J, Quintero AJ, Russ C. Jamieson MJ, et al. Am J Cardiovasc Drugs. 2022 Nov;22(6):615-631. doi: 10.1007/s40256-022-00524-x. Epub 2022 May 16. Am J Cardiovasc Drugs. 2022. PMID: 35570249 Free PMC article. Review.
Data from healthy volunteers and patients with nonvalvular atrial fibrillation (NVAF) or venous thromboembolism (VTE) have shown that increased body weight has a modest effect on apixaban's PK. However, the paucity of exposure data in individuals > 120 kg and the …
Data from healthy volunteers and patients with nonvalvular atrial fibrillation (NVAF) or venous thromboembolism (VTE) have shown that increa …
A Review of the Safety and Efficacy of Apixaban in Patients With Severe Renal Impairment.
Ifeanyi J, See S. Ifeanyi J, et al. Sr Care Pharm. 2023 Mar 1;38(3):86-94. doi: 10.4140/TCP.n.2023.86. Sr Care Pharm. 2023. PMID: 36803700 Review.
Background Apixaban is a direct-acting oral anticoagulant (DOAC) used to treat or prevent thromboembolic events. ...An in-depth literature search reveals substantial evidence supporting the safety and effectiveness of apixaban in ESRD. Clinicians must have access to …
Background Apixaban is a direct-acting oral anticoagulant (DOAC) used to treat or prevent thromboembolic events. ...An in-depth liter …
Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Proietti M, Romanazzi I, Romiti GF, Farcomeni A, Lip GYH. Proietti M, et al. Stroke. 2018 Jan;49(1):98-106. doi: 10.1161/STROKEAHA.117.018395. Epub 2017 Nov 22. Stroke. 2018. PMID: 29167388 Free article. Review.
Apixaban was as effective as dabigatran and rivaroxaban in reducing thromboembolic events and stroke. ...A better safety profile was found with apixaban compared with warfarin, dabigatran, and rivaroxaban....
Apixaban was as effective as dabigatran and rivaroxaban in reducing thromboembolic events and stroke. ...A better safety profile was …
3,547 results